Guardant Health, ConcertAI Working Together on Cancer Treatments

MT Newswires Live01-16

Guardant Health (GH) said Thursday it is partnering with ConcertAI to combine patient electronic medical records with their genomic and epigenomic tumor profiling data throughout their health care treatments for cancer.

Financial terms and other details of the agreement were not disclosed.

Concert AI is an oncology data and artificial intelligence software-as-a-service company.

Shares of Guardant Health were down more than 1% in recent trading activity.

Price: 37.01, Change: -0.49, Percent Change: -1.32

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment